Hemophilia
Conditions
Interventions
Hemophilia A inhibitor subjects receiving ITI treatment for the first time:NA
Hemophilia A inhibitor subjects receiving rescue treatment:NA
Hemophilia B inhibitor subjects:NA
Sponsors
Beijing Children's Hospital Affiliated to Capital Medical University
Eligibility
Sex/Gender
All
Age
No minimum to 18 Years
Inclusion criteria
Inclusion criteria: 1. Hemophilia A inhibitor subjects receiving ITI treatment for the first time: (1) hemophilia A severe (FVIII: C= 200BU, (4) inhibitors have not shown a decreasing trend after 3 months of ITI treatment, (5)FVIII immune tolerance induction therapy (FVIII 100IU/kg. QD or other regimen), combined with rituximab 375mg/m^2 each time, maximum single dose 600mg once a week for 2 weeks, and daratumumab 16mg/kg once a week for 2 weeks. 2. Hemophilia A inhibitor subjects receiving salvage treatment: (1) hemophilia A severe (FVIII: C= 100BU or re elevated or recurrent after 4-6 months of rituximab treatment; (4) Receive FVIII immune tolerance induction therapy (FVIII 100IU/kg. QD or other regimen) in combination with daratumumab 16mg/kg once a week for 4 consecutive weeks. 3. Hemophilia B inhibitor subjects: (1) hemophilia B severe (FIX: C= 0.6BU/ml. (4) Daretomumab 16mg/kg, once a week for 4 consecutive weeks, to be inhibited combined with FIX preventive treatment after the substance turns negative.
Exclusion criteria
Exclusion criteria: Merge with other coagulation related diseases, hematological disorders, autoimmune diseases, malignant tumors, etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Inhibitor; | — |
Countries
China
Contacts
Public ContactRunhui Wu
Beijing Children's Hospital Affiliated to Capital Medical University
Outcome results
None listed